search
Company Information
USD
154.64
- (0.2%)
NYSE:JNJ, JOHNSON & JOHNSON
Industry: Drug Manufacturers - General
End of Day: 17 May 2024 GMT-4
Johnson & Johnson is the world's largest and most diverse healthcare firm. Three divisions make up the firm: pharmaceutical, medical devices and diagnostics, and consumer. The drug and device groups represent close to 80% of sales and drive the majority of cash flows for the firm. The drug division focuses on the following therapeutic areas: immunology, oncology, neurology, pulmonary, cardiology, and metabolic diseases. The device segment focuses on orthopedics, surgery tools, vision care, and a few smaller areas. The last segment of consumer focuses on baby care, beauty, oral care, over-the-counter drugs, and women’s health. The consumer group is being divested in 2023 under the new name Kenvue. Geographically, just over half of total revenue is generated in the United States.

Address

One Johnson and Johnson Plaza

Classification

Sector

Healthcare

Industry Group

Drug Manufacturers

Industry

Drug Manufacturers - General

Key Executives

Ms. Anne M. Mulcahy
Director
Mr. D. Scott Davis
Director
Dr. John C. Reed,M.D.,PhD
Executive VP, Divisional
Ms. Marillyn A. Hewson
Director
Dr. Paula A. Johnson,M.D.
Director
Mr. Hubert Joly
Director
Dr. Peter M. Fasolo, PhD
Executive VP/Other Executive Officer
Dr. Mary C. Beckerle, PhD
Director
Mr. Darius E. Adamczyk
Director
Dr. Mark B. McClellan, M.D.,PhD
Director
Mr. Joaquin Duato
CEO/Chairman of the Board/Director
Dr. Jennifer A. Doudna
Director
Mr. Joseph J. Wolk
CFO/Executive VP
Mr. James D. Swanson
Chief Information Officer/Executive VP
Ms. Jennifer L. Taubert
Chairman, Divisional/Executive VP
Ms. Kathryn E. Wengel
Chief Risk Officer/Executive VP/Other Executive Officer
Mr. Eugene A. Woods
Director
Dr. Nadja Y West, M.D.
Director
Mr. Mark A. Weinberger
Director
Mr. Robert J. Decker, Jr
Chief Accounting Officer/Controller
Mr. William N. Hait, M.D.,PhD
Chief Medical Officer/Executive VP/Other Executive Officer
Ms. Vanessa Broadhurst
Executive VP, Divisional
Ms. Elizabeth Forminard
Executive VP/General Counsel
Mr. Timothy Schmid
Chairman, Divisional/Executive VP

Ownership

Institution Holdings

Vanguard Group Inc
229,387,626 (9.523%)
BlackRock Inc
186,308,341 (7.735%)
State Street Corporation
132,904,295 (5.518%)
Vanguard Investments Australia Ltd
76,902,644 (3.193%)
BlackRock Fund Advisors
68,712,977 (2.853%)
Fidelity Management & Research Company LLC
52,754,567 (2.190%)
Geode Capital Management, LLC
51,256,785 (2.128%)
Morgan Stanley - Brokerage Accounts
41,659,479 (1.729%)
SPDR State Street Global Advisors
33,836,954 (1.405%)
State Farm Mutual Automobile Ins Co
31,675,492 (1.315%)

Funds Holdings

Vanguard US Total Market Shares ETF
75,670,293 (3.141%)
Vanguard Total Stock Market Index Fund
75,670,293 (3.141%)
Vanguard Institutional 500 Index Trust
59,490,128 (2.470%)
Fidelity 500 Index Fund
28,581,052 (1.187%)
SPDR® S&P 500 ETF Trust
28,257,600 (1.173%)
iShares Core S&P 500 ETF
25,044,729 (1.040%)
Vanguard Value Index Fund
20,035,826 (0.832%)
Health Care Select Sector SPDR® Fund
18,234,519 (0.757%)
Vanguard Institutional Index Fund
15,921,739 (0.661%)
Vanguard Dividend Appreciation Index Fd
13,800,295 (0.573%)

Details

Overview Company Info Key Ratios Income Balance Sheet Cash Flow
Make Smart Investment Choices